Lupin's Goa facility may face regulatory action, says USFDA

The USFDA has stated that it may withhold approval of any pending
applications or supplements in which this facility is listed," it
added.

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/lupins-goa-facility-may-face-regulatory-action-says-usfda/articleshow/69586425.cms

Comments

Popular posts from this blog

NISER PhD Program Admission 2020-21 (Winter Session)

Data Analyst Jobs – Life Sciences Apply at Cognizant

Are hospitals prescribing the more expensive remdesivir instead of cheaper alternatives?